KRAS is altered in 17.89% of malignant solid tumor patients with KRAS Mutation present in 16.95% of all malignant solid tumor patients [4].

KRAS Mutation is an inclusion criterion in 55 clinical trials for malignant solid tumor, of which 36 are open and 19 are closed. Of the trials that contain KRAS Mutation and malignant solid tumor as inclusion criteria, 33 are phase 1 (20 open), 12 are phase 1/phase 2 (9 open), and 10 are phase 2 (7 open) [5].

KRAS is altered in 29.61% of non-small cell lung carcinoma patients with KRAS Mutation present in 29.07% of all non-small cell lung carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 52 clinical trials for non-small cell lung carcinoma, of which 37 are open and 15 are closed. Of the trials that contain KRAS Mutation and non-small cell lung carcinoma as inclusion criteria, 27 are phase 1 (20 open), 7 are phase 1/phase 2 (5 open), 16 are phase 2 (10 open), and 2 are phase 3 (2 open) [5].

KRAS is altered in 44.18% of colorectal carcinoma patients with KRAS Mutation present in 43.69% of all colorectal carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 33 clinical trials for colorectal carcinoma, of which 22 are open and 11 are closed. Of the trials that contain KRAS Mutation and colorectal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 20 are phase 1 (14 open), 7 are phase 1/phase 2 (5 open), and 5 are phase 2 (2 open) [5].

KRAS is altered in 4.45% of acute myeloid leukemia patients with KRAS Mutation present in 4.37% of all acute myeloid leukemia patients [4].

KRAS Mutation is an inclusion criterion in 12 clinical trials for acute myeloid leukemia, of which 8 are open and 4 are closed. Of the trials that contain KRAS Mutation and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), 4 are phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].

KRAS is altered in 2.9% of melanoma patients with KRAS Mutation present in 2.4% of all melanoma patients [4].

KRAS Mutation is an inclusion criterion in 12 clinical trials for melanoma, of which 9 are open and 3 are closed. Of the trials that contain KRAS Mutation and melanoma as inclusion criteria, 9 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

KRAS is altered in 86.36% of pancreatic carcinoma patients with KRAS Mutation present in 86.27% of all pancreatic carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 8 clinical trials for pancreatic carcinoma, of which 6 are open and 2 are closed. Of the trials that contain KRAS Mutation and pancreatic carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

KRAS is altered in 1.54% of myelodysplastic syndromes patients with KRAS Mutation present in 1.46% of all myelodysplastic syndromes patients [4].

KRAS Mutation is an inclusion criterion in 8 clinical trials for myelodysplastic syndromes, of which 6 are open and 2 are closed. Of the trials that contain KRAS Mutation and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 3 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

KRAS is altered in 1.99% of breast carcinoma patients with KRAS Mutation present in 0.85% of all breast carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 8 clinical trials for breast carcinoma, of which 4 are open and 4 are closed. Of the trials that contain KRAS Mutation and breast carcinoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (0 open) [5].

KRAS is altered in 44.33% of colorectal adenocarcinoma patients with KRAS Mutation present in 43.84% of all colorectal adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 7 clinical trials for colorectal adenocarcinoma, of which 6 are open and 1 is closed. Of the trials that contain KRAS Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 1 is phase 3 (1 open) [5].

KRAS is altered in 32.84% of lung adenocarcinoma patients with KRAS Mutation present in 32.29% of all lung adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 7 clinical trials for lung adenocarcinoma, of which 7 are open and 0 are closed. Of the trials that contain KRAS Mutation and lung adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [5].

KRAS is altered in 10.16% of ovarian carcinoma patients with KRAS Mutation present in 8.26% of all ovarian carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 7 clinical trials for ovarian carcinoma, of which 4 are open and 3 are closed. Of the trials that contain KRAS Mutation and ovarian carcinoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [5].

KRAS is altered in 13.2% of chronic myelomonocytic leukemia patients with KRAS Mutation present in 13.2% of all chronic myelomonocytic leukemia patients [4].

KRAS Mutation is an inclusion criterion in 6 clinical trials for chronic myelomonocytic leukemia, of which 5 are open and 1 is closed. Of the trials that contain KRAS Mutation and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

KRAS is altered in 4.45% of squamous cell lung carcinoma patients with KRAS Mutation present in 3.76% of all squamous cell lung carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 6 clinical trials for squamous cell lung carcinoma, of which 3 are open and 3 are closed. Of the trials that contain KRAS Mutation and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 4 are phase 2 (1 open) [5].

KRAS is altered in 1.42% of non-hodgkin lymphoma patients with KRAS Mutation present in 1.23% of all non-hodgkin lymphoma patients [4].

KRAS Mutation is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 4 are open and 2 are closed. Of the trials that contain KRAS Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [5].

KRAS is altered in 19.6% of endometrial carcinoma patients with KRAS Mutation present in 19.25% of all endometrial carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 5 clinical trials for endometrial carcinoma, of which 5 are open and 0 are closed. Of the trials that contain KRAS Mutation and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open) [5].

KRAS is altered in 86.35% of pancreatic adenocarcinoma patients with KRAS Mutation present in 86.25% of all pancreatic adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 4 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain KRAS Mutation and pancreatic adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 12.96% of multiple myeloma patients with KRAS Mutation present in 12.96% of all multiple myeloma patients [4].

KRAS Mutation is an inclusion criterion in 4 clinical trials for multiple myeloma, of which 4 are open and 0 are closed. Of the trials that contain KRAS Mutation and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), and 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 6.06% of bladder carcinoma patients with KRAS Mutation present in 5.43% of all bladder carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 4 clinical trials for bladder carcinoma, of which 2 are open and 2 are closed. Of the trials that contain KRAS Mutation and bladder carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (1 open) [5].

KRAS is altered in 13.39% of esophageal carcinoma patients with KRAS Mutation present in 4.17% of all esophageal carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 4 clinical trials for esophageal carcinoma, of which 2 are open and 2 are closed. Of the trials that contain KRAS Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (1 open) [5].

KRAS is altered in 80.56% of pancreatic ductal adenocarcinoma patients with KRAS Mutation present in 80.56% of all pancreatic ductal adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 2 are closed. Of the trials that contain KRAS Mutation and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

KRAS is altered in 43.92% of colon carcinoma patients with KRAS Mutation present in 43.32% of all colon carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for colon carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and colon carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [5].

KRAS is altered in 32.43% of non-squamous non-small cell lung carcinoma patients with KRAS Mutation present in 31.89% of all non-squamous non-small cell lung carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for non-squamous non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 3 (1 open) [5].

KRAS is altered in 18.96% of cholangiocarcinoma patients with KRAS Mutation present in 18.41% of all cholangiocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for cholangiocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

KRAS is altered in 16.61% of cancer patients with KRAS Mutation present in 15.74% of all cancer patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for cancer, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and cancer as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 2.52% of head and neck squamous cell carcinoma patients with KRAS Mutation present in 1.73% of all head and neck squamous cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 2 are closed. Of the trials that contain KRAS Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

KRAS is altered in 2.0% of glioma patients with KRAS Mutation present in 1.4% of all glioma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for glioma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and glioma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [5].

KRAS is altered in 0.98% of renal cell carcinoma patients with KRAS Mutation present in 0.98% of all renal cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for renal cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and renal cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 0.93% of hepatocellular carcinoma patients with KRAS Mutation present in 0.93% of all hepatocellular carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for hepatocellular carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

KRAS is altered in 1.14% of prostate carcinoma patients with KRAS Mutation present in 0.88% of all prostate carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for prostate carcinoma, of which 1 is open and 2 are closed. Of the trials that contain KRAS Mutation and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (0 open) [5].

KRAS Mutation is an inclusion criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

KRAS is altered in 50.0% of ampulla of vater carcinoma patients with KRAS Mutation present in 49.47% of all ampulla of vater carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for ampulla of vater carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and ampulla of vater carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

KRAS is altered in 32.39% of low grade ovarian serous adenocarcinoma patients with KRAS Mutation present in 32.39% of all low grade ovarian serous adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for low grade ovarian serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KRAS is altered in 13.46% of gastric carcinoma patients with KRAS Mutation present in 9.74% of all gastric carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [5].

KRAS is altered in 6.57% of histiocytic and dendritic cell neoplasm patients with KRAS Mutation present in 6.57% of all histiocytic and dendritic cell neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [5].

KRAS is altered in 5.52% of urothelial carcinoma patients with KRAS Mutation present in 4.89% of all urothelial carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KRAS is altered in 11.42% of adenocarcinoma of the gastroesophageal junction patients with KRAS Mutation present in 3.62% of all adenocarcinoma of the gastroesophageal junction patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 2 are closed. Of the trials that contain KRAS Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (0 open) [5].

KRAS is altered in 3.59% of poorly differentiated thyroid gland carcinoma patients with KRAS Mutation present in 3.59% of all poorly differentiated thyroid gland carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for poorly differentiated thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and poorly differentiated thyroid gland carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

KRAS is altered in 4.1% of small cell lung carcinoma patients with KRAS Mutation present in 3.54% of all small cell lung carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

KRAS is altered in 3.45% of low grade glioma patients with KRAS Mutation present in 3.24% of all low grade glioma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 3.01% of lymphoma patients with KRAS Mutation present in 2.77% of all lymphoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 2.41% of secondary acute myeloid leukemia patients with KRAS Mutation present in 2.41% of all secondary acute myeloid leukemia patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KRAS is altered in 2.41% of therapy-related acute myeloid leukemia patients with KRAS Mutation present in 2.41% of all therapy-related acute myeloid leukemia patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KRAS is altered in 2.38% of thyroid gland carcinoma patients with KRAS Mutation present in 2.38% of all thyroid gland carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

KRAS is altered in 2.61% of cutaneous melanoma patients with KRAS Mutation present in 2.06% of all cutaneous melanoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for cutaneous melanoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and cutaneous melanoma as inclusion criteria, 2 are phase 1 (2 open) [5].

KRAS is altered in 2.08% of diffuse large B-cell lymphoma patients with KRAS Mutation present in 1.89% of all diffuse large B-cell lymphoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [5].

KRAS is altered in 2.14% of head and neck carcinoma patients with KRAS Mutation present in 1.49% of all head and neck carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

KRAS is altered in 1.6% of glioblastoma patients with KRAS Mutation present in 0.96% of all glioblastoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for glioblastoma, of which 0 are open and 2 are closed. Of the trials that contain KRAS Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [5].

KRAS is altered in 0.8% of myelodysplastic syndrome with excess blasts-2 patients with KRAS Mutation present in 0.8% of all myelodysplastic syndrome with excess blasts-2 patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [5].

KRAS is altered in 0.53% of gastrointestinal stromal tumor patients with KRAS Mutation present in 0.53% of all gastrointestinal stromal tumor patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 0 are open and 2 are closed. Of the trials that contain KRAS Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [5].

KRAS is altered in 49.47% of malignant small intestinal neoplasm patients with KRAS Mutation present in 49.47% of all malignant small intestinal neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS is altered in 44.33% of malignant intestinal neoplasm patients with KRAS Mutation present in 43.86% of all malignant intestinal neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and malignant intestinal neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS is altered in 28.63% of lung carcinoma patients with KRAS Mutation present in 28.09% of all lung carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 17.19% of biliary tract carcinoma patients with KRAS Mutation present in 16.09% of all biliary tract carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 22.8% of germ cell tumor patients with KRAS Mutation present in 10.29% of all germ cell tumor patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS is altered in 13.46% of malignant gastric neoplasm patients with KRAS Mutation present in 9.74% of all malignant gastric neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and malignant gastric neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS is altered in 13.47% of gastric adenocarcinoma patients with KRAS Mutation present in 9.71% of all gastric adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS is altered in 24.87% of malignant testicular neoplasm patients with KRAS Mutation present in 9.05% of all malignant testicular neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant testicular neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and malignant testicular neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS is altered in 10.37% of malignant ovarian epithelial tumor patients with KRAS Mutation present in 8.31% of all malignant ovarian epithelial tumor patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS is altered in 10.49% of gallbladder carcinoma patients with KRAS Mutation present in 7.34% of all gallbladder carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 13.4% of malignant esophagogastric neoplasm patients with KRAS Mutation present in 6.48% of all malignant esophagogastric neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS is altered in 5.32% of malignant peripheral nerve sheath tumor patients with KRAS Mutation present in 5.32% of all malignant peripheral nerve sheath tumor patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 8.52% of mucosal melanoma patients with KRAS Mutation present in 5.11% of all mucosal melanoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 4.83% of papillary renal cell carcinoma patients with KRAS Mutation present in 4.83% of all papillary renal cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS is altered in 3.68% of pilocytic astrocytoma patients with KRAS Mutation present in 3.68% of all pilocytic astrocytoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 3.68% of myeloid neoplasm patients with KRAS Mutation present in 3.63% of all myeloid neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 2.82% of therapy-related myelodysplastic syndrome patients with KRAS Mutation present in 2.82% of all therapy-related myelodysplastic syndrome patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS is altered in 2.63% of embryonal rhabdomyosarcoma patients with KRAS Mutation present in 2.63% of all embryonal rhabdomyosarcoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 3.3% of squamous cell carcinoma patients with KRAS Mutation present in 2.58% of all squamous cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS is altered in 2.29% of thyroid gland follicular carcinoma patients with KRAS Mutation present in 2.29% of all thyroid gland follicular carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 2.25% of ganglioglioma patients with KRAS Mutation present in 2.25% of all ganglioglioma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 2.11% of thyroid gland undifferentiated (anaplastic) carcinoma patients with KRAS Mutation present in 2.11% of all thyroid gland undifferentiated (anaplastic) carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 1.76% of cervical squamous cell carcinoma patients with KRAS Mutation present in 1.76% of all cervical squamous cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS is altered in 2.22% of mantle cell lymphoma patients with KRAS Mutation present in 1.67% of all mantle cell lymphoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

KRAS is altered in 1.87% of neuroblastoma patients with KRAS Mutation present in 1.6% of all neuroblastoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 4.17% of high grade ovarian serous adenocarcinoma patients with KRAS Mutation present in 1.59% of all high grade ovarian serous adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS is altered in 1.83% of sarcoma patients with KRAS Mutation present in 1.45% of all sarcoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS is altered in 1.44% of oropharyngeal squamous cell carcinoma patients with KRAS Mutation present in 1.44% of all oropharyngeal squamous cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 1.42% of thyroid gland papillary carcinoma patients with KRAS Mutation present in 1.42% of all thyroid gland papillary carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland papillary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 1.55% of soft tissue sarcoma patients with KRAS Mutation present in 1.33% of all soft tissue sarcoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 1.99% of diffuse glioma patients with KRAS Mutation present in 1.3% of all diffuse glioma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 1.16% of neuronal and mixed neuronal-glial tumors patients with KRAS Mutation present in 1.16% of all neuronal and mixed neuronal-glial tumors patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 1.76% of astrocytic tumor patients with KRAS Mutation present in 1.04% of all astrocytic tumor patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 1.01% of kidney carcinoma patients with KRAS Mutation present in 1.01% of all kidney carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for kidney carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and kidney carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS is altered in 0.85% of chronic myeloid leukemia patients with KRAS Mutation present in 0.85% of all chronic myeloid leukemia patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 1.94% of breast adenocarcinoma patients with KRAS Mutation present in 0.76% of all breast adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and breast adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS is altered in 2.6% of anaplastic astrocytoma patients with KRAS Mutation present in 0.65% of all anaplastic astrocytoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS is altered in 0.39% of pleural mesothelioma patients with KRAS Mutation present in 0.39% of all pleural mesothelioma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS is altered in 0.32% of mesothelioma patients with KRAS Mutation present in 0.32% of all mesothelioma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS is altered in 0.25% of clear cell renal cell carcinoma patients with KRAS Mutation present in 0.25% of all clear cell renal cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for primary peritoneal low grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and primary peritoneal low grade serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 0.98% of thymic carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].